Except, if another BP makes a larger counter offer, or a 3rd gets involved.
IF they can see an Autism, Parkinsons prize they know what they will have to bid. It aint gonna be just $50.
The Risk is all theirs after tomorrow.
Many Big Pharmas need to replenish their pipelines for the next 20yr period. They also have a lot of cash in their piggy banks. And interest rates look like they are dropping.
NEU have a very significant pipeline. What was the last count? About 40 indications?
The longer it goes, the more results will arrive, adding more pressure on BP. With John just quietly mentioning NEUs own preparing and progress for Phase 3 trials along the way, just to keep the pressure on.
NEU and shareholders may well be about to have one hell of a year. Or a very short spectacular period during the year.
This could/should be one for the ages.
GLTAH
.
NEU Price at posting:
$17.14 Sentiment: Buy Disclosure: Held
(20min delay)